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ABSTRACT 
Background: Despite the beneficial effects of glycoprotein (GP) lib/Ilia 
antagonists in patients with unstable angina nd non-ST-segment elevation myo- 
cardial infarction (UA/NSTEMI), GP IIb/IIIa antagonists are rarely administered 
in general internal medicine wards in Israel, where most patients with UA/ 
NSTEMI are admitted, due to lack of adequate monitoring and safety concerns. 
Objective: The aims of this study were to compare the prevalence of bleed- 
ing complications in patients with UA/NSTEMI receiving combination treatment 
with eptifibatide (a GP IIb/IIIa antagonist), the low-molecular-weight heparin enoxa- 
parin, and acetylsalicylic a id (ASA) versus that in patients receiving enoxaparin 
and ASA in internal medicine wards in Israel, and to identify risk factors for 
bleeding complications. 
Methods: This retrospective analysis included information from the data- 
base at Rambam Medical Center, Haifa, Israel. The database provided informa- 
tion from 4 of the 5 wards (the ward from which data were unavailable did not 
routinely use eptifibatide). Data were included from patients aged ___18 years 
who were admitted to the center with a diagnosis of UA/NSTEMI, were at high 
risk for death and/or nonfatal ischemic events based on American College of 
Cardiology/American Heart Association guidelines, were to undergo coronary 
intervention, and who had a Thrombosis in Myocardial Infarction risk score 
---3 (moderate to high risk). Patients in the eptifibatide group received eptifi- 
batide IV (180-pg/kg bolus followed by a continuous infusion of 2 pg/kg • min 
up to 72 hours), enoxaparin SC (2 mg/kg • d), and ASA (100 mg/d). Patients in 
the control group received enoxaparin SC (2 mg/kg • d up to 96 hours) and ASA 
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(100 mg/d). The prevalence of bleeding events was assessed using data up to 
24 hours after the end of study drug administration. Major bleeding was defined 
as life-threatening bleeding at any site, intracranial hemorrhage, or bleeding 
accompanied by a decrease in plasma hemoglobin concentration of 5 g/dL 
or more. Otherwise, bleeding was considered minor. The risk for bleeding 
events was assessed using multivariate regression analysis. 
Results: Data from 105 patients (64 men, 41 women) were included in the analy- 
sis. In the eptifibatide and control groups, the mean (SD) ages were 68.7 (11.1) 
and 74.8 (11.0) years, respectively. These characteristics were statistically simi- 
lar between the 2 groups. The rates of major bleeding were similar between 
the eptifibatide and control groups (2 [3.8%] vs 0 patients). The rate of minor 
bleeding was significantly higher in the eptifibatide group compared with that 
in controls (11 [21.2%] vs 4 [7.5%] patients; P= 0.03). The incidence of thrombo- 
cytopenia was statistically similar between the eptifibatide and control groups 
(0 vs 2 [3.8%] patients). The risk for bleeding was found to be associated with 
eptifibatide use (odds ratio, 4.8; 95% CI, 1.29-17.80), whereas an association 
with treatment was not found in the control group. 
Conclusion: The results of this retrospective analysis uggest that the risk 
for bleeding complications i higher with combination treatment with eptifi- 
batide, enoxaparin, and ASA compared with that with enoxaparin and ASA in 
high-risk patients with UA/NSTEMI admitted to internal medicine wards in 
Israel. (Curt Ther Res Clin Exp. 2005;66:501-510) Copyright © 2005 Excerpta 
Medica, Inc. 
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INTRODUCTION 
Ischemic heart disease (IHD) is the leading cause of morbidity and mortality in 
developed countries. Acute coronary syndromes (ACSs) comprise a spectrum 
of cardiac disorders, from unstable angina and non-ST-segment myocardial 
infarction (UA/NSTEMI) to ST-segment elevation and sudden cardiac death. Over 
the past decade, ACSs have been found to be a consequence of atheromatous 
plaque rupture leading to abrupt coronary artery occlusion and myocardial 
ischemia. 1 
Inhibition of platelet activity at the site of the injured coronary plaque is the 
first-line treatment ofACSs with non-ST-segment elevation. Heparin and acetyl- 
salicylic acid (ASA) are the cornerstones of antithrombotic treatment in these 
patients. Clinical trials in the past decade have found that drugs that block gly- 
coprotein (GP) IIb/IIIa receptor activity have an incremental benefit in reducing 
the frequency of adverse outcomes, beyond that of treatment with heparin and 
ASA, in patients with ACS with non-ST-segment elevation. 2-7 
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Eptifibatide is a small, synthetic, cyclic heptapeptide that is a specific antag- 
onist of GP IIb/IIIa receptor activity. It was modeled after a compound isolated 
from pygmy rattlesnake venom. It inhibits platelet function in a dose-specific 
fashion by reversibly binding the platelet GP IIb/IIIa receptor. 8 
Clinical trials have found that treatment with a GP IIb/IIIa antagonist in com- 
bination with unfractionated heparin (UH) or low-molecular-weight heparin 
(LMWH) is associated with an increased risk for bleeding and thrombocytope- 
nia. 5,9-11 A meta-analysis of clinical trials designed to determine the efficacy and 
tolerability of GP IIb/IIIa inhibitors in patients with UA/NSTEMI found that the 
prevalence of major bleeding was increased with the use of GP IIb/IIIa inhibitors 
compared with no treatment (2.4% vs 1.4%; P < 0.001). 7 The prevalences of 
minor bleeding in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor 
Suppression Using Integrilin Therapy (PURSUIT) study 5in 10,948 patients with 
an ACS were 11.1% and 4.7% with the use of eptifibatide and placebo, respec- 
tively (P < 0.02), whereas the rates of thrombocytopenia were similar between 
the 2 treatments (6.9% and 7.0%, respectively). 
At Rambam Medical Center in Haifa, Israel (a 900-bed tertiary hospital with 
180 beds divided among 5 wards in the Division of General Internal Medicine), 
most patients with UA/NSTEMI are admitted to general internal medicine wards. 
We hypothesized that combination therapy with eptifibatide, heparin, and ASA 
would be well tolerated, despite limited monitoring, in patients admitted to the 
hospital with UA/NSTEMI and a high risk for adverse outcomes. At the time of 
this study, eptifibatide was the only GP IIb/IIIa antagonist used in the hospital. 
In 3 wards, eptifibatide was used routinely as part of the antithrombotic regi- 
men for high-risk patients with UA/NSTEMI scheduled to undergo coronary angi- 
ography and revascularization. The remaining 2wards did not use eptifibatide 
but instead used routine anticoagulation therapy with LMWH and ASA. 
The goals of this study were to compare the tolerability of combination treat- 
ment with eptifibatide, the LMWH enoxaparin, and ASA with that of a combina- 
tion of enoxaparin and ASA in high-risk patients admitted to Rambam Medical 
Center, and to identify risk factors for bleeding. 
MATERIALS AND METHODS 
The hospital database, which provided information from 4 of the 5 wards (the 
ward from which data were unavailable did not routinely use eptifibatide), was 
used to search for patients whose data were eligible for inclusion in the analy- 
sis. Data from patients aged ___18 years admitted between March 1, 2003, and 
January 31, 2004, to the Department ofGeneral Internal Medicine with a diagno- 
sis of UA/NSTEMI and/or unstable angina pectoris, and who were at high risk for 
adverse outcomes, as assessed by the attending physician using the Thrombosis 
in Myocardial Infarction (TIMI) risk scale (described later), 12,13 were included. 
No institutional review board or ethics committee approval was required for 
this retrospective analysis. Only high-risk patients were included based on the 
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American College of Cardiology/American Heart Association guidelines for the 
management of patients with UA/NSTEMI, 14 which state that the use of eptifibatide 
or any other  GP IIb/IIIa antagonists hould be reserved for pat ients in whom 
catheter izat ion and percutaneous  coronary  intervent ion are planned, those 
with continuing ischemia or elevated troponin concentration, or those with 
other high-risk features in whom invasive treatment is not planned. 
The 7-item TIMI risk scale 12,13 was developed by Antman et a113 to assess the 
risk for adverse outcomes in patients with UA/NSTEMI. Moderate- to high-risk 
patients are those who have at least 3 of the following risk factors: 
• Age ---65 years; 
• At least 3 risk factors for IHD (diabetes mellitus, hypertension, hypercho- 
lesterolemia, smoking, and/or family history of IHD); 
• Known significant IHD; 
• Recent severe angina pectoris, defined as ischemic hest pain lasting ___10 min- 
utes (___2 episodes in the prior 24 hours); 
• ASA use in the previous 7 days; 
• ST-T deviation ---0.5 mm; and 
• Elevated cardiac markers in the serum (troponin I [normal value (NV), 
___0.2 ng/mL] or creatinine kinase isoenzyme MB [CK-MB] concentration).  
Data from patients with a TIM112'13 risk score ---3, with at least 2 of the risk cri- 
teria scored 1 to 5, and at least 1 risk criterion scored 6 or 7, were included. 
Exclusion Criteria 
Data were excluded if a patient had bleeding risk (defined as active bleeding 
in the previous 3 months, systolic/diastolic blood pressure >200/>110 mm Hg, 
platelet count <100 × 109 cells/L, history of cerebral hemorrhage or known intra- 
cerebral  vascular  disease, nonhemorrhag ic  stroke in the previous 4 weeks, 
and/or major surgery in the previous 6 weeks), received concomitant therapy 
with another GP IIb/IIIa antagonist, had renal failure (estimated plasma creati- 
nine concentrat ion >2.5 mg/dL), or had a known allergy to GP IIb/IIIa antago- 
nists, LMWH, or ASA. 
Study Groups 
Patients found in the database search were categorized into 2 groups based 
on whether eptifibatide was administered. The eptifibatide group comprised pa- 
tients treated with eptifibatide IV (180 1Jg/kg bolus, followed by a continuous in- 
fusion of 2 1Jg/kg • min up to 72 hours), enoxaparin SC (2 mg/kg • d up to 96 hours), 
and ASA (100 mg/d). The control group comprised patients treated with enoxa- 
parin SC (2 mg/kg • d) and ASA (100 mg/d). 
Assessments 
From each patient's medical file, the following data were collected in addition 
to those used to determine inclusion: sex; history of IHD and/or myocardial 
infarction; chest pain or congestive heart failure on admission to the hospital; 
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length of hospital stay; data concerning urgent diagnostic atheterization a d 
revascularization (ie, percutaneous coronary intervention or coronary artery 
bypass grafting) during hospitalization; and data concerning adverse effects 
related to eptifibatide use (eg, bleeding, thrombocytopenia). 
Tolerability 
Bleeding Events 
Each day, the attending physicians in the participating wards monitored 
patients for adverse vents, including bleeding, site of bleeding, and thrombo- 
cytopenia. Bleeding events were quantified according to TIM112'13 criteria. Major 
bleeding was defined as life-threatening bleeding from any site, intracranial 
hemorrhage, or bleeding accompanied by a decrease in plasma hemoglobin 
concentration of at least 5 g/dL. Otherwise, bleeding was considered minor. 15 
Thrombocytopenia 
Data concerning thrombocytopenia, defined as a platelet count <100,000 cells/pL 
or a decrease of 50% from the baseline count, were also collected. 
Statistical Analysis 
The data from the 2 treatment groups were compared using the )~2 test. To 
assess the main effect of case study dependence, a logistic regression model 
was assembled using different variables (age, TIMI risk score, development of
congestive heart failure, and eptifibatide treatment). A 2-sided P < 0.05 was 
considered statistically significant. 16Data were analyzed using SPSS version 11 
(SPSS Inc., Chicago, Illinois) and are expressed as mean (SD). 
RESULTS 
The database search found 250 patients who were admitted to the hospital, of 
whom 105 patients (64 men, 41 women) were eligible for inclusion in the analy- 
sis. The mean (SD) ages of patients whose data were included in the eptifibatide 
group (52 patients) and control group (53 patients) were 68.7 (11.1) and 74.8 
(11.0) years, respectively (Table I). Fifty-nine patients had a history of IHD. 
Hypertension, diabetes mellitus, hyperlipidemia, smoking habit, chest pain, and 
family history of IHD occurred at similar rates between the 2 groups, and the 
mean TIMI risk scores and mean serum troponin I concentrations were statisti- 
cally similar. 
A significantly higher proportion of the eptifibatide group underwent diagnos- 
tic catheterization compared with the control group (33 [63.5%] vs 21 [39.6%] 
patients; P = 0.019). The rates of urgent revascularization were statistically sim- 
ilar between the eptifibatide and control groups (20/33 [60.6%] vs 11/21 [52.4%] 
patients). 
The prevalences ofbleeding events are summarized in Table II. Major bleed- 
ing was reported in 2 (3.8%) patients in the eptifibatide group and in none of the 
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Table I. Baseline demographic and clinical characteristics of the study patients. 
Eptifibatide Control 
Characteristic (n = 52) (n = 53) 
Age 
Mean (SD), y 68.7 (11.1) 74.8 (11.0) 
No. (%) of patients 
aged >65 y 42 (80.8) 43 (81.1) 
Sex, no. (%) 
Male 33 (63.5) 31 (58.5) 
Female 19 (36.5) 22 (41.5) 
History of IHD, no. (%) 27 (51.9) 32 (60.4) 
History of acute MI, no. (%) 21 (40.4) 28 (52.8) 
IHD risk factor, no. (%) 
Hypertension 33 (63.5) 43 (81.1) 
Hyperlipidemia 30 (57.7) 32 (60.4) 
Smoking habit 26 (50.0) 26 (49.1) 
Type 2 diabetes mellitus 22 (42.3) 22 (41.5) 
Family history of IHD 10 (19.2) 10 (18.9) 
Hospital data 
Chest pain on admission, no. (%) 49 (94.2) 44 (83.0) 
CHF on admission, no. (%) 9 (1 7.3) 12 (22.6) 
LOS, mean (SD), d 9.1 (8.8)* 6.4 (4.6) 
Diagnostic catheterization, no. (%) 33 (63.5) t 21 (39.6) 
Urgent revascularization, no. (%) 20/33 (60.6) 11/21 (52.4) 
TIMI ~12,13 score, mean (SD) 4.3 (1.18) 3.7 (0.7) 
Troponin I, mean (SD), ng/mL 13.6 (14.8) 13 (19.1 ) 
ASA use <7 days, no. (%) 7 (13.5) 7 (13.2) 
ST-T deviation ->0.5 ram, no. (%) 40 (76.9) 38 (71.7) 
IHD = ischemic heart disease; MI = myocardial infarction; CHF = congestive heart failure; LOS = length 
of stay; TIMI = Thrombosis in Myocardial Infarction; ASA = acetylsalicylic acid. 
*P = 0.002 versus control group. 
tp = 0.019 versus control group. 
~The TIMI scale is used for assessing risk for adverse outcomes. Patients at moderate to high risk have 
3 or more of the following risk factors: (1) age _>65 years; (2) at least 3 risk factors for IHD; (3) known 
significant IHD; (4) recent severe angina pectoris, defined as ischemic chest pain lasting _>10 minutes 
(_>2 episodes in the previous 24 hours); (5) ASA use within the previous 7 days; (6) STT deviation _>0.5 ram; 
and (7) elevated cardiac markers (serum concentrations: troponin I, >0.2 ng/mL; or creatinine kinase 
isoenzyme, >10.8 U/L). 
patients in the control group; this difference was not significant. Both of these 
patients had bleeding accompanied by a decrease in hemoglobin concentration 
of at least 5 g/dL. One of these patients had bleeding in the upper gastrointesti- 
nal tract that required a blood transfusion; the other patient, who was bleeding 
from 2 sites, had macroscopic hematuria nd hemoptysis requiring fluid re- 
placement. No bleeding-related deaths occurred in either group. 
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Table II. Bleeding events and thrombocytopenia in patients receiving treatment with 
eptif ibatide, enoxaparin, and acetylsalicylic acid (ASA) (eptif ibatide group) 
or enoxaparin and ASA (control group) for unstable angina and non-ST- 
segment elevation myocardial infarction. Values are no. (%) of patients. 
Eptifibatide Control 
Parameter (n = 52) (n = 53) 
Any bleeding event 
Any major bleeding event * 
Any minor bleeding event§ll 
Thrombocytopenia tl 
13 (25.0)* 4 (7.5) 
2 (3.8) 0 
11 (21.2)* 4 (7.5) 
0 2 (3.8) 
*P = 0.03 versus control group. 
fMajor bleeding event was defined as life-threatening bleeding at any site, intracranial hemorrhage, or 
bleeding accompanied by a decrease in plasma hemoglobin concentration of 5 g/dL or more. 
~95% CI, 1.4%-9.1 %. 
§Minor bleeding event was defined as any bleeding event not considered major. 
IIApproximately half of these bleeding events occurred at sites of vascular puncture. 
qlplatelet count <100,000 cells/pL. 
The rate of minor bleeding events was significantly higher in the eptifibatide 
group compared with the control group (11 [21.2%] vs 4 [7.5%] patients; P = 
0.03). Approximately half of the minor bleeding episodes were at the sites of 
vascular puncture. The prevalences ofthrombocytopenia were statistically sim- 
ilar between the eptifibatide and control groups (0 vs 2 [3.8%] patients). 
The mean (SD) duration of hospital stay was significantly longer in the epti- 
fibatide group compared with that in the control group (9.1 [8.8] vs 6.4 [4.6] days; 
P = 0.002) (Table I). 
As shown in Table Ill, multivariate regression analysis found that the only 
significant risk factor for bleeding was eptifibatide use (odds ratio, 4.8; 95% CI, 
1.29-17.80). 
DISCUSSION 
GP IIb/IIIa antagonists combined with ASA and either UH or LMWH have been 
found to be efficacious and well tolerated in patients with UA/NSTEMI. 9,17,18 The 
present study was undertaken to examine the tolerability and feasibility of GP 
IIb/IIIa antagonist use in the setting of general internal medicine wards in Israel, 
where the level of monitoring is less intensive than in the coronary care wards. 
The rate of major bleeding events (3.8%) was consistent with those from other, 
large-scale trials (1%-10%). 6,14 Our cohort displayed a higher prevalence of mi- 
nor bleeding events compared with those found in the various studies (13% 
and 3%, respectively). 9'17'19 We observed a rate of minor bleeding of 21.2% in 
eptifibatide-treated patients, with approximately half of the incidences occur- 
ring at the puncture sites for vascular catheters. 
The approach to eptifibatide-treated patients was more aggressive than that 
in the control group. This finding might be due to the fact that, although the 
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Table III. Association of all bleeding events with age, Thrombosis in Myocardial Infarc- 
t ion (TIMI) 12A3. score, development  of congestive heart fai lure (CHF), and 
ept i f ibat ide use (N = 105). 
P Eptifibatide 
Variable Versus Control OR 95% CI 
Age ->76 years 0.20 2.18 0.67-7.14 
TIMI score ->3 0.66 0.75 0.20-2.74 
Development of CHF 0.77 1.24 0.28-5.51 
Eptifibatide treatment 0.02 4.80 1.29-1 7.8 
OR = odds ratio. 
*The TIMI scale is used for assessing risk for adverse outcomes. Patients at moderate to high risk have 
3 or more of the following risk factors: (1) age _>65 years; (2) at least 3 risk factors for ischemic heart 
disease (IHD); (3) known significant IHD; (4) recent severe angina pectoris, defined as ischemic chest 
pain lasting _>10 minutes (_>2 episodes in the previous 24 hours); (5) acetylsalicylic acid use within the 
previous 7 days; (6) ST-T deviation _>0.5 ram; and (7) elevated cardiac markers (serum concentrations: 
troponin I, >0.2 ng/mL; or creatinine kinase isoenzyme, >10.8 U/L). 
department of general internal medicine in our hospital comprises 5 wards, 
there are variations in the therapeutic approach to UA/NSTEMI. Wards that 
used eptifibatide in high-risk patients had a higher rate of catheterization i
these patients. In the eptifibatide group, the more frequent use of invasive man- 
agement might have been related to the longer hospital stay and the higher 
rates of bleeding events. Notably, Budaj et al 2° found striking variations in the 
implementation of the guidelines for approaching patients with UA/NSTEMI 
between geographic areas and hospitals worldwide. 
This study was limited by several factors, including the retrospective analysis 
of the data; the open-label, uncontrolled esign; the lack of randomization; and 
between-group differences in baseline characteristics, management, and follow-up. 
In addition, the power to detect differences was low due to the small number of 
patients. 
CONCLUSION 
The results of this retrospective analysis uggest that the risk for bleeding com- 
plications is higher with combination treatment with eptifibatide, enoxaparin, 
and ASA compared with that with enoxaparin and ASA in high-risk patients with 
UA/NSTEMI admitted to internal medicine wards in Israel. 
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